David Cairns

24PUBLICATIONS
69CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Medical mycologyHaematological tumoursPredictive and prognostic markersImmunogenetics (incl. genetic immunology)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (24)

|Mar 30, 2026
Patient-reported health-related quality of life in previously untreated chronic lymphocytic leukaemia: Results from the randomised phase 3 FLAIR trial comparing ibrutinib-rituximab versus fludarabine-cyclophosphamide-rituximab.

David J Allsup, David A Cairns, E Faye Samy

|Aug 20, 2025
Challenging the concept of functional high-risk myeloma through transcriptional and genetic profiling.

Sina A Beer, David A Cairns, Charlotte Pawlyn

|Feb 18, 2025
Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma.

Martin F Kaiser, Pieter Sonneveld, David A Cairns

|Aug 12, 2024
Progression-free survival as a surrogate endpoint in myeloma clinical trials: an evolving paradigm.

Charlotte Pawlyn, Fredrik H Schjesvold, David A Cairns

|Mar 19, 2024
Progression free survival of myeloma patients who become IFE-negative correlates with the detection of residual monoclonal free light chain (FLC) by mass spectrometry.

H V Giles, M T Drayson, B Kishore

|Jan 10, 2024
Impact of minimal residual disease (MRD) in salvage autologous stem cell transplantation for relapsed myeloma: results from the NCRI Myeloma X (intensive) trial.

Ruth M de Tute, Gordon Cook, David A Cairns

Pageof 4

Frequent Collaborators

13 joint publications

Martin Kaiser

11 joint publications

Charlotte Pawlyn

10 joint publications

Gordon Cook

5 joint publications

Graham Jackson